Annals of Hematology

, Volume 89, Issue 7, pp 691–699

A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs

  • Elena Crisà
  • Ermanno Venturino
  • Roberto Passera
  • Marco Prina
  • Piercarla Schinco
  • Alessandra Borchiellini
  • Valentina Giai
  • Maria Ausilia Ciocca Vasino
  • Mario Bazzan
  • Antonella Vaccarino
  • Mario Boccadoro
  • Dario Ferrero
Original Article

DOI: 10.1007/s00277-009-0899-z

Cite this article as:
Crisà, E., Venturino, E., Passera, R. et al. Ann Hematol (2010) 89: 691. doi:10.1007/s00277-009-0899-z

Abstract

The clinical impact of polycythemia vera (PV) diagnostic and therapeutic guidelines is still undetermined. In particular, the recommended target of hematocrit (Hct) <0.45 has been recently questioned and alkylating drugs are still used for elderly patients. We revised, according to WHO criteria, 300 PV diagnosis and evaluated the impact on clinical outcome of median Hct and of the strategy to administer anti-thrombotic prophylaxis and to avoid alkylating chemotherapy in almost all patients. Of 226 patients with WHO-confirmed diagnosis (median age 66), 91.3% survived at the median follow-up of 5.84 years and 77.5% are projected alive at 13 years. Eighteen percent had major thrombosis and 2.7% acute myeloid leukemia. Twenty-two percent of patients maintained an Hct <0.45: their overall and thrombosis-free survival are similar to those of patients with a 0.45–0.48 value. Conversely, an Hct >0.48 and a “high thrombotic risk” according to ECLAP criteria were both significantly associated to shorter survival and higher thrombosis risk. Chemotherapy reduced thrombotic events without affecting survival. Our study revealed suboptimal compliance to published guidelines. However, in our casistic characterized by wide use of anti-platelet- and avoidance of alkylating drugs, patients’ survival, although analyzed retrospectively, seemed to have improved compared to old literature data. The optimal Hct target was not clearly defined, although a value <0.48 looks highly advisable.

Keywords

Polycythemia vera Thrombotic events Chemotherapy Hematocrit Acute myeloid leukemia 

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Elena Crisà
    • 1
  • Ermanno Venturino
    • 2
  • Roberto Passera
    • 3
  • Marco Prina
    • 2
  • Piercarla Schinco
    • 1
  • Alessandra Borchiellini
    • 1
  • Valentina Giai
    • 1
  • Maria Ausilia Ciocca Vasino
    • 4
  • Mario Bazzan
    • 5
  • Antonella Vaccarino
    • 5
  • Mario Boccadoro
    • 1
  • Dario Ferrero
    • 1
  1. 1.Divisione di Ematologia dell’ Università di TorinoAzienda Ospedaliera S. Giovanni Battista di TorinoTurinItaly
  2. 2.S.I.M.T. Banca del SangueAzienda Ospedaliera S. Giovanni Battista di TorinoTurinItaly
  3. 3.Medicina Nucleare IIAzienda Ospedaliera S. Giovanni Battista di TorinoTurinItaly
  4. 4.Divisione Ospedaliera di EmatologiaAzienda Ospedaliera S. Giovanni Battista di TorinoTurinItaly
  5. 5.Ambulatorio di EmatologiaCasa di Cura “Cellini”TurinItaly

Personalised recommendations